Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Pediatric Drugs
Erschienen in: Pediatric Drugs 5/2014

01.10.2014 | Therapy in Practice

Management of Treatment-Resistant Depression in Children and Adolescents

verfasst von: Melissa DeFilippis, Karen Dineen Wagner

Erschienen in: Pediatric Drugs | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Depression is a relatively common diagnosis in children and adolescents, and is associated with significant morbidity and suicidality in this population. Evidence-based treatment of the acute illness is imperative to try to prevent the development of treatment-resistant depression or other complications. In situations where response to acute treatment is inadequate, clinicians should first consider factors that may influence outcome, such as psychiatric or medical comorbidities, psychosocial stressors, and treatment noncompliance. Selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for depression in children and adolescents. For treatment-resistant depression, a switch to an alternate SSRI is recommended before trials of other antidepressants. Psychotherapy, such as cognitive behavioral therapy or interpersonal therapy, may improve treatment response. More research is needed examining medication augmentation strategies for treatment-resistant depression in children and adolescents.
Literatur
1.
Merikangas KR, He J, Burstein M, Swanson SA, Avenevoli S, Cui L, Benjet C, Georgiades K, Swendsen J. Lifetime prevalence of mental disorders in US adolescents: Results from the National Comorbidity Study-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010;49(10):980–9.PubMedCrossRefPubMedCentral
2.
Melvin GA, Dudley AL, Gordon MS, Ford S, Taffe J, Tonge BJ. What happens to depressed adolescents? A follow-up study into early adulthood. J Affective Disorders. 2013;151:298–305.CrossRef
3.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Association; 2013.
4.
Williams JM, et al. Pre-adult onset and patterns of suicidality in patients with a history of recurrent depression. J Affect Disord. 2012;138(1–2):173–9.PubMedCrossRefPubMedCentral
5.
Brent D, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: The TORDIA randomized controlled trial. JAMA. 2008;299(8):901–13.PubMedCrossRefPubMedCentral
6.
Wagner KD, Pliszka SR. Treatment of child and adolescent disorders. In: Schatzberg AF, Nemeroff CB, editors. Essentials of clinical psychopharmacology, 3rd ed. Arlington, VA: American Psychiatric Publishing; 2013. p. 693–750.
7.
Malouf FT, Atwi M, Brent DA. Treatment-resistant depression in adolescents: review and updates on clinical management. Depress Anxiety. 2011;28:946–54.CrossRef
8.
Lewinsohn PM, et al. Cross-sectional and prospective relationships between physical morbidity and depression in older adolescents. J Am Acad Child Adolesc Psychiatry. 1996;35:1120–9.PubMedCrossRef
9.
Kovacs M, et al. Psychiatric disorder and metabolic control among youths with IDDM. A longitudinal study. Diabetes Care. 1996;19:318–23.PubMedCrossRef
10.
Schosser A, Kasper S. The role of pharmacogenetics in the treatment of depression and anxiety disorders. Int Clin Psychopharmacol. 2009;24:277–88.PubMedCrossRef
11.
Emslie GJ, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54(11):1031–7.PubMedCrossRef
12.
Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised (DHEW Publ No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. p. 218–22.
13.
Emslie GJ, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002;41(10):1205–15.PubMedCrossRef
14.
Poznanski EO, Mokros H. Children’s Depression Rating Scale Revised (CDRS-R)Western Psychological Services, Los Angeles; 1996.
15.
March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J. Treatment for Adolescents With Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004;292(7):807–20.PubMedCrossRef
16.
Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry. 2009;48(7):721–9.PubMedCrossRef
17.
Wagner KD, et al. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry. 2006;45(3):280–8).
18.
Wagner KD, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. Sertraline Pediatric Depression Study Group. JAMA. 2003;290(8):1033–41.PubMedCrossRef
19.
Wagner KD, et al. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry. 2004;161(6):1079–83.PubMedCrossRef
20.
21.
Emslie GJ, et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2006;45(6):709–19.PubMedCrossRef
22.
von Knorring AL, et al. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol. 2006;26(3):311–5.CrossRef
23.
Emslie GJ, et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2006;45(6):709–19.PubMedCrossRef
24.
Berard R, et al. An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2006;16(1–2):59–75.PubMedCrossRef
25.
Keller MB, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001;40(7):762–72.PubMedCrossRef
26.
Emslie, Yeung, and Kunz. Long-term, open-label venlafaxine extended-release treatment in children and adolescents with major depressive disorder. CNS Spectrums. 2007;12(3):223-233.
27.
Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry. 2005;46:735–54.PubMedCrossRef
28.
A Study in the Treatment of Children and Adolescents with Major Depressive Disorder, Clinicaltrials.gov Study NCT00849901 and Study NCT00849693.
29.
Delbello MP, et al. A double-blind, placebo-controlled study of selegeline transdermal system (EMSAS) in depressed adolescents. In: Presented at Annual Meeting of American Academy of Child and Adolescent Psychiatrists Annual Meeting, Toronto, Canada, 18–23 Oct 2011.
30.
Daviss WB, et al. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry. 2001;40(3):307–14.PubMedCrossRef
31.
Bridge JA, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta analysis of randomized controlled trials. JAMA. 2007;297(15):1683–96.PubMedCrossRef
32.
Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2012;11:CD004851. doi:10.​1002/​14651858.​CD004851.​pub3.
33.
Kennard BD, Silva SG, Tonev S, Rohde P, Hughes JL, Vitiello B, Kratochvil CJ, Curry JF, Emslie GJ, Reinecke M, March J. Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes. J Am Acad Child Adolesc Psychiatry. 2009;48(2):186–95.PubMedCrossRefPubMedCentral
34.
The TADS Team. The treatment for adolescents with depression study (TADS). Arch Gen Psychiatry. 2007;64:1132–44.CrossRef
35.
Emslie GJ, Kennard BD, Mayes TL, Nightingale-Teresi J, Carmody T, Hughes CW, Rush AJ, Tao R, Rintelmann JW. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry. 2008;165(4):459–67.PubMedCrossRefPubMedCentral
36.
37.
Birmaher B. Brent D; AACAP Work Group on Quality Issues, Bernet W, Bukstein O, Walter H, Benson RS, Chrisman A, Farchione T, Greenhill L, Hamilton J, Keable H, Kinlan J, Schoettle U, Stock S, Ptakowski KK, Medicus J. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007;46(11):1503–26.PubMedCrossRef
38.
Hughes CW, Emslie GJ, Crismon ML, Posner K, Birmaher B, Ryan N, Jensen P, Curry J, Vitiello B, Lopez M, Shon SP, Pliszka SR, Trivedi MH. Texas consensus conference panel on medication treatment of childhood major depressive disorder. Texas children’s medication algorithm project: update from Texas consensus conference panel on medication treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(6):667–86.PubMedCrossRef
39.
Emslie GJ, Kennard BD, Mayes TL. Predictors of treatment response in adolescent depression. Pediatr Ann. 2011;40(6):300–6.PubMedCrossRef
40.
41.
Emslie GJ, Mayes T, Porta G, et al. Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes. Am J Psychiatry. 2010;167(7):782–91.PubMedCrossRefPubMedCentral
42.
Beach SR, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry. 2014;75(5):e441–9.PubMedCrossRef
43.
Zivin K, et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40mg. Am J Psychiatry. 2013;170:642–50.PubMedCrossRef
44.
Van Haelst IMM, et al. QT interval prolongation in users of selective serotonin reuptake inhibitors in an elderly surgical population: a cross-sectional study. J Clin Psychiatry. 2014; 75(1):15-21
45.
46.
Jerrell JM. Neuroendocrine-related adverse events associated with antidepressant treatment in children and adolescents. CNS Neurosci Therapeutics. 2010;16:83–90.CrossRef
47.
Voican CS, et al. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry. 2014;171(4):404–15.PubMedCrossRef
48.
Hammerness PG, et al. Selective serotoinin reuptake inhibitors in pediatric psychopharmacology: a review of the evidence. J Pediatrics. 2006;148:158–65.CrossRef
49.
50.
Cooper WO, et al. Antidepressants and suicide attempts in children. Pediatrics. 2014;133(2):204–10.PubMedCrossRef
51.
Miller M, et al. Antidepressant dose, age, and the risk of deliberate self-harm. JAMA Intern Med. 2014;174(6):899–909.PubMedCrossRef
52.
Pathak S, Johns ES, Kowatch RA. Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series. J Child Adolesc Psychopharmacol. 2005;15(4):696–702.PubMedCrossRef
53.
Nemets H, et al. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry. 2006;163(6):1098–100.PubMedCrossRef
54.
Bloch Y, et al. Repetitive transcranial magnetic stimulation in the treatment of depression in adolescents: an open-label study. J ECT. 2008;24(2):156–9.PubMedCrossRef
55.
Mayer G, et al. Long-term follow-up of adolescents with resistant depression treated with repetitive transcranial magnetic stimulation. J ECT. 2012;28(2):84–6.PubMedCrossRef
56.
Walter G, et al. Transcranial magnetic stimulation in young persons: a review of known cases. J Child Adolsec Psychopharmacol. 2001;11(1):69–75.CrossRef
57.
Hegeman JM, et al. The efficacy of electroconvulsive therapy in adolescents. A restrospective study. Tijdschr Psychiatr. 2008;50(1):23–51.PubMed
58.
Ghaziuddin N, et al. Use of continuation or maintenance electroconvulsive therapy in adolescents with severe treatment-resistant depression. J ECT. 2011;27(2)168–74.
59.
Ghaziuddin N, et al. Work Group on Quality Issues; AACAP. Practice parameter for use of electroconvulsive therapy with adolescents. J Am Acad Child Adoles Psychiatry. 2004;43:1521–39.CrossRef
60.
Brent DA, et al. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch Gen Psychiatry. 1997;54(9):877–85.PubMedCrossRef
61.
Clarke GN, Rohde P, Lewinsohn PM, Hops H, Seeley JR. Cognitive-behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions. J Am Acad Child Adolesc Psychiatry. 1999;38(3):272–9.PubMedCrossRef
62.
Lewinsohn PM, Clarke GN, Hops H, Andrews J. Cognitive-behavioral treatment for depressed adolescents. Behavioral Therapy. 1990;21:385–401.CrossRef
63.
Rosselló J, Bernal G. The efficacy of cognitive-behavioral and interpersonal treatments for depression in Puerto Rican adolescents. J Consult Clin Psychol. 1999;67(5):734–45.PubMedCrossRef
64.
Wood A, Harrington R, Moore A. Controlled trial of a brief cognitive-behavioural intervention in adolescent patients with depressive disorders. J Child Psychol Psychiatry. 1996;37(6):737–46.PubMedCrossRef
65.
Weisz JR, McCarty CA, Valeri SM. Effects of psychotherapy for depression in children and adolescents: a meta-analysis. Psychol Bull. 2006;132(1):132–49.PubMedCrossRefPubMedCentral
66.
Merry SN, et al. The effectiveness of SPARX, a computerized self help intervention for adolescents seeking help for depression: randomized controlled non-inferiority trial. BMJ. Published online Apr 18 2012. doi:10.​1136/​bmj.​e2598.
67.
Mufson L, Dorta KP, Wickramaratne P, Nomura Y, Olfson M, Weissman MM. A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry. 2004;61(6):577–84.PubMedCrossRef
68.
Mufson L, Weissman MM, Moreau D, Garfinkel R. Efficacy of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry. 1999;56(6):573–9.PubMedCrossRef
69.
Tang TC, Jou SH, Ko CH, Huang SY, Yen CF. Randomized study of school-based intensive interpersonal psychotherapy for depressed adolescents with suicidal risk and parasuicide behaviors. Psychiatry Clin Neurosci. 2009;63(4):463–70.PubMedCrossRef
70.
Young JF, Mufson L, Gallop R. Preventing depression: a randomized trial of interpersonal psychotherapy-adolescent skills training. Depress Anxiety. 2010;27(5):426–33.PubMedCrossRefPubMedCentral
71.
Kratochvil C, et al. Acute time to response in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006;45(12):1412–8.PubMedCrossRef
72.
Curry J, et al. Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006;45(12):1427–39.PubMedCrossRef
73.
Kennard BD, et al. Cognitive-behavioral therapy to prevent relapse in pediatric responders to pharmacotherapy for major depressive disorder. J Am Acad Child Adolesc Psychiatry. 2008;47(12):1395–404.PubMedCrossRefPubMedCentral
74.
Goodyer IM, et al. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial. Health Technol Assess. 2008;12(14):iii–iv, ix-60.
75.
Dubicka B, Elvins R, Roberts C, Chick G, Wilkinson P, Goodyer I. Combined treatment with cognitive-behavioural therapy in adolescent depression: meta-analysis. B J Psych. 2010;197:433–40.CrossRef
76.
Cox GR et al. Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents (Review). Cochrane Database Syst Rev. 2012;11:CD008324. doi:10.​1002/​14651858.​CD008324.​pub2.
77.
Diamond GS, et al. Attachment-based family therapy for adolescents with suicidal ideation: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2010;49(2):122–31.PubMed
Metadaten
Titel
Management of Treatment-Resistant Depression in Children and Adolescents
verfasst von
Melissa DeFilippis
Karen Dineen Wagner
Publikationsdatum
01.10.2014
Verlag
Springer International Publishing
Erschienen in
Pediatric Drugs / Ausgabe 5/2014
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-014-0088-y

Weitere Artikel der Ausgabe 5/2014

Pediatric Drugs 5/2014 Zur Ausgabe

Original Research Article

Results from a Nationwide Cohort Temporary Utilization Authorization (ATU) Survey of Patients in France Treated with Pheburane® (Sodium Phenylbutyrate) Taste-Masked Granules

Original Research Article

Statin Use in Australian Children: A Retrospective Audit of Four Pediatric Hospitals

Adis Drug Evaluation

10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D-Conjugate Vaccine: A Review in Infants and Children

Original Research Article

The EU Paediatric Regulation: Still a Large Discrepancy Between Therapeutic Needs and Approved Paediatric Investigation Plans

Leading Article

Long-Term Safety of Immunomodulators in Pediatric Inflammatory Diseases

Review Article

Pharmacological Management of Narcolepsy and Cataplexy in Pediatric Patients

Neu im Fachgebiet Pädiatrie

23.04.2024 | Typ-1-Diabetes | Nachrichten

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

22.04.2024 | Fehlsichtigkeit | Nachrichten

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

18.04.2024 | Spinale Muskelatrophien | Nachrichten

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind
weitere anzeigen

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen